Efficacy and Safety Study of DURVALUMAB Maintenance in Patients With Stage III Non-Small Cell Lung Cancer

A Study to Determine Safety of Durvalumab After Sequential Chemo Radiation in Patients With Unresectable Stage III Non-Small Cell Lung Cancer

NCT03693300 ·Status: COMPLETED ·Phase: PHASE2

A French Real-life Study: EvaluatioN of durvALumab Utilization and Effectiveness for First Line Extensive Stage Small Cell Lung Cancer.

NCT05683977 ·Status: ACTIVE_NOT_RECRUITING

Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE)

NCT05925530 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy.

NCT04642469 ·Status: COMPLETED ·Phase: PHASE3

Durvalumab Plus Etoposide-free Chemotherapy in First-line Treatment of Extensive-disease Small-sell Lung Cancer (SCLC)

NCT05856695 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

AGNOSTIC THERAPY IN A PHASE II SINGLE-ARM STUDY IN FIRST-LINE TREATMENT OF DURVALUMAB IN ASSOCIATION WITH CARBOPLATIN OR CISPLATIN AND ETOPOSIDE IN PATIENTS AFFECTED BY EXTENSIVE STAGE - EXTRAPULMONARY SMALL CELL CARCINOMA

NCT06464068 ·Status: RECRUITING ·Phase: PHASE2

Durvalumab and Chemotherapy Induction Followed by Durvalumab and Radiotherapy in Large Volume Stage III NSCLC

NCT04765709 ·Status: TERMINATED ·Phase: PHASE2

Immune Neoadjuvant Therapy Study of Durvalumab in Early Stage Non-small Cell Lung Cancer

NCT03030131 ·Status: TERMINATED ·Phase: PHASE2

Real Life Second-Line Nivolumab in Advanced Non-Small Cell Lung Cancer

NCT04858204 ·Status: COMPLETED

Durvalumab as Consolidation Therapy in Patients With LS-SCLC Following sCRT

NCT07309211 ·Status: RECRUITING

A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC

NCT05211895 ·Status: RECRUITING ·Phase: PHASE3

Durvalumab and Low-dose PCI vs Durvalumab and Observation in Radically Treated Patients With Stage III NSCLC (NVALT28)

NCT04597671 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC

NCT03822351 ·Status: COMPLETED ·Phase: PHASE2

Durvalumab Combined With Consolidation Radiotherapy After First-line Treatment in Extensive Stage Small Cell Lung Cancer With Oligometastases

NCT05484583 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Chemo-immunotherapy, Hypo-fractionated RT and Maintenance Immunotherapy for Stage III NSCLC.

NCT05128630 ·Status: RECRUITING ·Phase: PHASE2

Durvalumab in Combination With Standard Chemotherapy of Patients With Extensive Stage Small Cell Lung Cancer

NCT05761977 ·Status: UNKNOWN

Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer

NCT03519971 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

A Study of Durvalumab Plus Tremelimumab With Chemotherapy in Untreated ES-SCLC

NCT03963414 ·Status: TERMINATED ·Phase: PHASE1

Durvalumab After Concurrent Chemoradiotherapy (cCRT) for Limited-stage Small-cell Lung Cancer (LS-SCLC)

NCT07050472 ·Status: COMPLETED

Efficacy and Safety of PEMbrolizumab PD-L1-positive (>50% of Tumor Cells), Advanced NSCL Cancer(PEMBREIZH)

NCT05321212 ·Status: COMPLETED

Combination of Durvalumab and Tremelimumab as Maintenance Treatment in Patients With Non Squamous and Squamous (NSCLC)

NCT03319316 ·Status: WITHDRAWN ·Phase: PHASE2

Quick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung Cancer

NCT05696782 ·Status: RECRUITING ·Phase: PHASE2

D-BACE in Combination With Chemotherapy and Carelizumab for Resectable II-IIIA or Potentially Resectable T3-4N2 Stage IIIB NSCLC

NCT07016126 ·Status: RECRUITING ·Phase: PHASE3

Study of AZD2811 + Durvalumab in ES-SCLC

NCT04745689 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Study to Evaluate KOS-1584 in Patients With Advanced or Metastatic Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)

NCT00651508 ·Status: COMPLETED ·Phase: PHASE2